Domenico Iacopetta, Jessica Ceramella, Alessia Catalano*, Camillo rosano, Annaluisa Mariconda, Federica Giuzio, Daniela Bonofiglio, Carmela Saturnino, Pasquale Longo and Maria Stefania Sinicropi Pages 1 - 21 ( 21 )
Breast cancer (BC) currently represents one of the most prevalent cancers among women worldwide and the leading cause of cancer death among women, also negatively affecting the quality of life (QoL) in patients. Over the past two decades, BC research has led to extraordinary advances in our understanding of the disease, resulting in more effective treatments. However, its occurrence is still increasing. Several new treatments are now under development worldwide, but they are not devoid of well-- known side effects, and a great number of patients develop endocrine resistance. Nevertheless, the design and synthesis of more suitable strategies and new drugs to treat breast cancers, overcome resistance and side effects, and obtain better therapeutic outcomes are needed. In this review, we summarize the therapies and the clinical studies currently ongoing in Italy for the treatment of BCs, mainly HER2+ MBC, HER2-low MBC, and TNBC, focusing on the most recent ones, also in consideration of diverse facets, including some aspects related to QoL. Finally, some studies related to the usefulness of physical activity in BC will be cited.
Breast cancer,HER2+ MBC,TNBC,HER2-low BCs,clinical studies,QoL,physical activity